Clinical trial
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
NCT03415854 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
- Lead sponsor
- HonorHealth Research Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2018
- Completion date
- December 11, 2023
- Enrollment
- 34 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, pancreas metastases, pancreatic adenocarcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma